JPH10120554A - Quickly dispersible particle containing inorganic antiacid, and its production and internal medicine to be suspended on use - Google Patents
Quickly dispersible particle containing inorganic antiacid, and its production and internal medicine to be suspended on useInfo
- Publication number
- JPH10120554A JPH10120554A JP29450396A JP29450396A JPH10120554A JP H10120554 A JPH10120554 A JP H10120554A JP 29450396 A JP29450396 A JP 29450396A JP 29450396 A JP29450396 A JP 29450396A JP H10120554 A JPH10120554 A JP H10120554A
- Authority
- JP
- Japan
- Prior art keywords
- antacid
- inorganic
- particles
- dispersing
- sugar alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001458 anti-acid effect Effects 0.000 title claims abstract description 44
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 239000002245 particle Substances 0.000 title abstract description 37
- 239000003814 drug Substances 0.000 title description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 15
- 239000012736 aqueous medium Substances 0.000 claims abstract description 12
- 238000001694 spray drying Methods 0.000 claims abstract description 10
- 239000000725 suspension Substances 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 5
- 239000004375 Dextrin Substances 0.000 claims abstract description 5
- 229920001353 Dextrin Polymers 0.000 claims abstract description 5
- 229930195725 Mannitol Natural products 0.000 claims abstract description 5
- 229940024546 aluminum hydroxide gel Drugs 0.000 claims abstract description 5
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims abstract description 5
- 235000019425 dextrin Nutrition 0.000 claims abstract description 5
- 239000000594 mannitol Substances 0.000 claims abstract description 5
- 235000010355 mannitol Nutrition 0.000 claims abstract description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 43
- 229940069428 antacid Drugs 0.000 claims description 42
- 239000003159 antacid agent Substances 0.000 claims description 42
- 239000008187 granular material Substances 0.000 claims description 42
- 239000007884 disintegrant Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- -1 magnesium metasilicate aluminate Chemical class 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 229950008138 carmellose Drugs 0.000 claims description 4
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 4
- 239000000347 magnesium hydroxide Substances 0.000 claims description 4
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 229920002261 Corn starch Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 239000008120 corn starch Substances 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 3
- 239000001095 magnesium carbonate Substances 0.000 claims description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 229940088417 precipitated calcium carbonate Drugs 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- PGZIKUPSQINGKT-UHFFFAOYSA-N dialuminum;dioxido(oxo)silane Chemical compound [Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O PGZIKUPSQINGKT-UHFFFAOYSA-N 0.000 claims description 2
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 claims description 2
- 229960001545 hydrotalcite Drugs 0.000 claims description 2
- 229910001701 hydrotalcite Inorganic materials 0.000 claims description 2
- 150000002484 inorganic compounds Chemical class 0.000 claims 1
- 229910010272 inorganic material Inorganic materials 0.000 claims 1
- 229960001708 magnesium carbonate Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 24
- 210000002784 stomach Anatomy 0.000 abstract description 8
- 201000006549 dyspepsia Diseases 0.000 abstract description 7
- 239000006185 dispersion Substances 0.000 abstract description 6
- 206010000087 Abdominal pain upper Diseases 0.000 abstract description 3
- 230000029087 digestion Effects 0.000 abstract description 3
- 230000002496 gastric effect Effects 0.000 abstract description 3
- 206010020601 Hyperchlorhydria Diseases 0.000 abstract description 2
- 230000001133 acceleration Effects 0.000 abstract description 2
- 208000022531 anorexia Diseases 0.000 abstract description 2
- 206010061428 decreased appetite Diseases 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract description 2
- 210000001015 abdomen Anatomy 0.000 abstract 1
- 208000024798 heartburn Diseases 0.000 abstract 1
- 208000024981 pyrosis Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 21
- 239000000047 product Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Chemical class 0.000 description 2
- 150000002736 metal compounds Chemical class 0.000 description 2
- 229910000000 metal hydroxide Inorganic materials 0.000 description 2
- 150000004692 metal hydroxides Chemical class 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000018893 Cercis canadensis var canadensis Nutrition 0.000 description 1
- 240000000024 Cercis siliquastrum Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、無機制酸剤、糖アルコ
ール及び崩壊剤を均一に分散させ、噴霧乾燥させること
により得られる、極めて短時間に水媒質に懸濁分散可能
な、無機制酸剤含有速分散性造粒物及びその製造方法に
関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an inorganic antacid, sugar alcohol and disintegrant obtained by uniformly dispersing and spray-drying an inorganic antacid, a sugar alcohol and a disintegrant, which can be suspended and dispersed in an aqueous medium in a very short time. The present invention relates to an acid agent-containing rapidly dispersible granulated product and a method for producing the granulated product.
【0002】[0002]
【従来技術】医療用制酸剤は、消化促進、消化不良、食
欲不振、食べ過ぎ、胃もたれ、胸つかえ、消化不良によ
る胃部・腹部膨満感、胃痛、胃酸過多等の症状の改善に
用いられる。これらは、通常、細粒剤、顆粒剤及び錠剤
等の固形剤として又は液剤として用いられる。これら細
粒剤、顆粒剤及び錠剤は、軽量であり、嵩張らないので
携帯には便利であるが、服用後の胃内での崩壊や分散に
時間を要し、迅速に制酸作用を出現させるとういう面で
は問題があった。また、錠剤等は有効量を投与すると形
状が大きくなり、健常人でも服用時に咽頭や食道に付着
し、滞留することがよく起こりうる。特に咀嚼力や嚥下
力が劣る小児や老人のために飲みやすく改良した制酸剤
の開発が望まれていた。上記問題点を改善する方法とし
て懸濁液剤があるが、懸濁液剤は、細粒剤、顆粒剤及び
錠剤等の固形剤よりも制酸作用の発現が早い点では優れ
ているが、液剤であるがため容器の包装形態が大きく、
重量があることから携帯に不便であり、また、服用時に
は均一懸濁分散化が必要であること、保管中に経時的な
微生物の増菌化や、含有成分の安定性等に多くの問題点
があった。2. Description of the Related Art Medical antacids are used for improving symptoms such as acceleration of digestion, indigestion, loss of appetite, overeating, leaning of the stomach, chest stomach, stomach / abdominal distension due to indigestion, stomach pain, and gastric hyperacidity. Can be These are usually used as solid preparations such as fine granules, granules and tablets or as liquid preparations. These fine granules, granules and tablets are lightweight and non-bulky, so they are convenient to carry, but they take time to disintegrate and disperse in the stomach after taking them, and quickly show antacid action. There was a problem in that respect. In addition, tablets and the like become large in shape when administered in an effective amount, and often adhere to the pharynx and esophagus and take a stagnation during administration even in healthy individuals. In particular, there has been a demand for the development of an antacid that is easy to drink and improved for children and the elderly, who have poor chewing and swallowing power. Suspensions are a method of solving the above problems. Suspensions are superior in that they exhibit an antacid action earlier than solids such as fine granules, granules, and tablets. Because of this, the packaging form of the container is large,
Due to its weight, it is inconvenient to carry, and it requires uniform suspension and dispersion when taking it.There are many problems with the enrichment of microorganisms over time during storage and the stability of contained components. was there.
【0003】[0003]
【発明が解決しようとする課題】本発明は、無機制酸
剤、糖アルコール及び崩壊剤を均一に分散させ、噴霧乾
燥させることにより得られる、極めて短時間に水媒質に
懸濁分散可能な、無機制酸剤含有速分散性造粒物及びそ
の製造方法を提供することを目的とする。より詳しく
は、携帯に便利で、服用時、水媒質に極めて迅速に均一
に懸濁分散し、且つ違和感を持たずに服用し得る細粒状
無機制酸剤含有速分散性造粒物を提供することを目的と
する。DISCLOSURE OF THE INVENTION The present invention relates to an inorganic antacid, a sugar alcohol and a disintegrant which are uniformly dispersed and spray-dried, and can be suspended and dispersed in an aqueous medium in a very short time. An object of the present invention is to provide a fast-dispersing granule containing an inorganic antacid and a method for producing the same. More specifically, the present invention provides a fine-granular inorganic antacid-containing fast-dispersing granule that is convenient to carry, can be rapidly and uniformly suspended and dispersed in an aqueous medium when taken, and can be taken without giving a sense of incongruity. The purpose is to:
【0004】[0004]
【課題を解決するための手段】本発明者らは、上記課題
を解決するために鋭意研究を重ねた結果、水媒質中で無
機制酸剤、糖アルコール及び崩壊剤を均一に分散させ、
噴霧乾燥させることにより得られる無機制酸剤含有速分
散性造粒物が、上記問題点を解決し得ることを見し、本
発明に至った。本発明の無機制酸剤含有速分散性造粒物
は、粒子強度の硬い細粒であるにもかかわらず、この粒
子を水に分散させると1〜3分内という極めて短時間
に、均一に分散した懸濁液となる。Means for Solving the Problems The present inventors have conducted intensive studies to solve the above problems, and as a result, uniformly disperse the inorganic antacid, sugar alcohol and disintegrant in an aqueous medium,
The present inventors have found that a rapidly dispersible granule containing an inorganic antacid obtained by spray-drying can solve the above-mentioned problems, and have reached the present invention. Although the inorganic antacid-containing fast-dispersing granules of the present invention are hard fine particles having a high particle strength, when these particles are dispersed in water, they can be uniformly dispersed in an extremely short time of 1 to 3 minutes. It becomes a dispersed suspension.
【0005】本発明において用いられる無機制酸剤とし
ては、水に不溶性の金属酸化物、金属水酸化物、金属酸
塩又は複合金属化合物等が用いられる。より具体的に
は、酸化マグネシウム等の金属酸化物、乾燥水酸化アル
ミニウムゲル、水酸化アルミニウムゲル、水酸化マグネ
シウム等の金属水酸化物、沈降炭酸カルシウム、炭酸マ
グネシウム等の金属炭酸塩、又はメタケイ酸アルミン酸
マグネシウム、ケイ酸アルミン酸マグネシウム、水酸化
アルミナマグネシア、合成ヒドロタルサイト等の複合金
属化合物等の群から選ばれる1種以上を挙げることがで
きる。好ましくは、無機制酸剤が水酸化アルミニウムゲ
ル、炭酸マグネシウム、メタケイ酸アルミン酸マグネシ
ウム、ケイ酸アルミン酸マグネシウム、合成ヒドロキシ
タルサイト、乾燥水酸化アルミニウムゲル、水酸化マグ
ネシウム、沈降炭酸カルシウムの群から選ばれる1種以
上の組み合わせである。As the inorganic antacid used in the present invention, water-insoluble metal oxides, metal hydroxides, metal salts or composite metal compounds are used. More specifically, metal oxides such as magnesium oxide, dried aluminum hydroxide gel, aluminum hydroxide gel, metal hydroxides such as magnesium hydroxide, precipitated calcium carbonate, metal carbonates such as magnesium carbonate, or metasilicic acid At least one selected from the group consisting of composite metal compounds such as magnesium aluminate, magnesium silicate aluminate, magnesia hydroxide alumina, and synthetic hydrotalcite can be given. Preferably, the inorganic antacid is selected from the group consisting of aluminum hydroxide gel, magnesium carbonate, magnesium metasilicate aluminate, magnesium aluminate silicate, synthetic hydroxytalcite, dry aluminum hydroxide gel, magnesium hydroxide, precipitated calcium carbonate. One or more combinations.
【0006】これら無機制酸剤の配合量は、無機制酸剤
含有速分散性造粒物の全量に対して通常50〜95重量
%、好ましくは70〜95重量%、より好ましくは70
〜85重量%である。なお、これらの無機制酸剤は天然
物または合成によって得られるものであってもよく、す
でに粉末となったものを用いる場合にはできるだけ粉砕
して微粉として用いる方がよい。粒子径としては、15
μm以下のものが好ましい。The amount of the inorganic antacid is usually 50 to 95% by weight, preferably 70 to 95% by weight, more preferably 70 to 95% by weight, based on the total amount of the inorganic antacid-containing fast-dispersing granules.
~ 85% by weight. In addition, these inorganic antacids may be natural products or those obtained by synthesis, and when using those already in powder form, it is better to pulverize as much as possible and use them as fine powder. The particle size is 15
Those having a size of μm or less are preferred.
【0007】糖アルコールとしては、糖類の分子内の還
元性末端基が水素添加又は加水分解することにより得ら
れるものであり、原料糖の違いにより種々の糖アルコー
ルがある。本発明ではいずれを用いてもよくまた併用し
てもよい。具体的には、例えば、ソルビトール、マンニ
トール、キシリトール、還元麦芽糖水飴、エリスリトー
ル、マルチトール、ラクチトール又はパラチニット等を
挙げることができ、好ましくは、ソルビトール、マンニ
トール、キシリトール、還元麦芽糖水飴、エリスリトー
ル等である。これらの糖アルコールの配合量は、本発明
の無機制酸剤含有速分散性造粒物の全量に対して1〜3
5重量%、好ましくは1〜25重量%、より好ましくは
5〜20重量%である。[0007] The sugar alcohol is obtained by hydrogenating or hydrolyzing a reducing terminal group in the molecule of the saccharide, and there are various sugar alcohols depending on the difference of the raw sugar. In the present invention, any of these may be used or they may be used in combination. Specific examples include sorbitol, mannitol, xylitol, reduced maltose syrup, erythritol, maltitol, lactitol or palatinit, and the like, and preferably sorbitol, mannitol, xylitol, reduced maltose syrup, erythritol and the like. The mixing amount of these sugar alcohols is 1 to 3 with respect to the total amount of the inorganic antacid-containing fast-dispersing granules of the present invention.
It is 5% by weight, preferably 1 to 25% by weight, more preferably 5 to 20% by weight.
【0008】崩壊剤としては、デンプン系、セルロース
系、ビニール系等の崩壊剤が用いられる。より具体的に
は、トウモロコシデンプン、ばれいしょでんぷん、デキ
ストリン、ヒドロキシプロピルスターチ、部分アルファ
化デンプン、カルボキシメチルスターチナトリウム等の
デンプン系崩壊剤、カルメロースカルシウム、カルメロ
ース、架橋カルボキシメチルセルロースナトリウム、低
置換度ヒドロキシプロピルセルロース等のセルロース系
崩壊剤、架橋ポリビニルピロリドン等のビニル系崩壊剤
からなる群から選ばれる1種以上を適宜組み合わせて用
いることができる。好ましくは、トウモロコシデンプ
ン、デキストリン、カルメロースカルシウム、部分アル
ファー化デンプンからなる群から選ばれる1種以上の組
み合わせである。これらの配合量は、無機制酸剤含有速
分散性造粒物の全量に対して1〜15重量%、好ましく
は5〜10重量%である。As the disintegrant, disintegrants of starch type, cellulose type, vinyl type and the like are used. More specifically, corn starch, potato starch, dextrin, hydroxypropyl starch, partially pregelatinized starch, starch disintegrants such as sodium carboxymethyl starch, carmellose calcium, carmellose, cross-linked sodium carboxymethyl cellulose, low-substituted hydroxypropyl One or more selected from the group consisting of cellulose-based disintegrants such as cellulose and vinyl-based disintegrants such as cross-linked polyvinyl pyrrolidone can be used in appropriate combination. Preferably, it is at least one combination selected from the group consisting of corn starch, dextrin, carmellose calcium, and partially pregelatinized starch. The amount of these components is 1 to 15% by weight, preferably 5 to 10% by weight, based on the total amount of the inorganic antacid-containing rapidly dispersible granules.
【0009】本発明の無機制酸剤含有速分散性造粒物に
は上記成分のほかに、ケイヒ、チョウジ、赤芽柏、カン
ゾウ等の生薬類、ジメチルポリシロキサン又はシリコン
樹脂等の消泡剤、パラオキシ安息香酸メチル、安息香酸
ナトリウム等の防腐剤、ハッカ油、メントール、レモン
油等の香料、サッカリンナトリウム、グリチルリチン酸
等の甘味剤等を必要に応じて加えることができる。これ
らの成分は、医薬品や食品等の製造に際し、一般的に用
いられるものを適宜、単独または組合せて使用すること
ができる。[0009] In addition to the above components, the inorganic antacid-containing fast-dispersing granules of the present invention may further contain crude drugs such as cinnamon, clove, red bud, licorice, etc .; Preservatives such as methyl benzoate and sodium benzoate, flavors such as peppermint oil, menthol and lemon oil, and sweeteners such as saccharin sodium and glycyrrhizic acid can be added as required. As these components, those commonly used in the production of pharmaceuticals, foods and the like can be used alone or in combination as appropriate.
【0010】本発明の無機制酸剤含有速分散性造粒物の
調製は、湿式造粒方法であるが、噴霧乾燥造粒機にて行
うことを特徴とする。一方、通常の湿式造粒方法で、加
水練合機、押し出し造粒機、撹拌造粒機又は転動造粒機
等で調製した場合は、原料粉体に水を加えて練合や造粒
する時に練り込みによる圧密が加わるため、造粒物が高
密度で且つ凝集性の強い物性となり、その結果得られた
造粒物は水への分散性が悪いものとなる。また、高密度
の造粒物の物性を改善するために水の一部をエタノール
等の有機溶媒に換える手段もあるが、有機溶媒量が多く
なると乾燥後の造粒物は形状が崩れやすくなり、粉立ち
が激しく、且つ流動性が悪くなる等取扱上不便となる。
水と有機溶媒の最適混合比を設定し、目的とする物性を
有する造粒物を得ることは至難であることに加え、造粒
物に有機溶媒が残留する等問題もあり、好ましい方法で
はない。The preparation of the rapidly dispersible granules containing an inorganic antacid according to the present invention is a wet granulation method, which is characterized in that the granulation is carried out by a spray drying granulator. On the other hand, when prepared by a conventional wet granulation method using a water kneading machine, an extrusion granulator, a stirring granulator or a tumbling granulator, water is added to the raw material powder to knead or granulate. Since the consolidation due to kneading is added at the time of mixing, the granulated material has high density and strong cohesive properties, and as a result, the obtained granulated material has poor dispersibility in water. There is also a means of replacing a part of water with an organic solvent such as ethanol in order to improve the physical properties of the high-density granulated material.However, when the amount of the organic solvent is large, the dried granulated material tends to lose its shape. It is inconvenient to handle such as severe powdering and poor fluidity.
Setting the optimum mixing ratio of water and the organic solvent, it is extremely difficult to obtain a granulated product having the desired physical properties, and there is a problem that the organic solvent remains in the granulated product, which is not a preferable method. .
【0011】本発明の無機制酸剤含有速分散性造粒物
は、噴霧乾燥造粒法を用いて水系で調製することがで
き、下記の特徴ある物性を有する。すなわち、得られた
造粒物はマイクロスコープ(キーエンスVH−610
0)での観察から細粒状の球形物であり、且つ極めて流
動性が良く(安息角が31〜34°)、後工程での輸
送、混合及び分包等においてほとんど粒子の崩れがな
く、しかも造粒物がポーラスな凝集体となるため水媒質
に均一に分散し易い特徴を有し、1〜3分以内という極
めて短時間に、均一に分散した懸濁液剤となる。この優
れた物性を有する本発明の無機制酸剤含有速分散性造粒
物を有効成分として含有することを特徴とする用時懸濁
内服用制酸剤として使用することができる。The rapidly dispersible granules containing an inorganic antacid according to the present invention can be prepared in an aqueous system by using a spray drying granulation method, and have the following characteristic properties. That is, the obtained granules were obtained using a microscope (Keyence VH-610).
Observation at 0) shows that the product is a fine-grained sphere, has extremely good fluidity (angle of repose is 31 to 34 °), and has almost no particle collapse during transportation, mixing, and packaging in a later step. Since the granulated material is a porous aggregate, it has a characteristic of being easily dispersed uniformly in an aqueous medium, and becomes a uniformly dispersed suspension in an extremely short time of 1 to 3 minutes or less. The inorganic antacid-containing fast-dispersing granules containing the inorganic antacid of the present invention having excellent physical properties can be used as an antacid for internal use in suspension when used, which is characterized by containing as an active ingredient.
【0012】本発明の造粒物が、細粒状で且つ粒子強度
が硬く、水への分散性がよい物性をもたらす機構は次の
ように推定できる。すなわち、糖アルコールが噴霧乾燥
造粒時に無機制酸剤の凝集粒子間に介在し収縮性を抑え
る働きをすると同時に、その一部が粒子表面に析出し皮
膜形成するために水濡れが良くなり、その結果として細
粒状の粒子内の崩壊剤へ水を呼び込み易くすることによ
り、分散性が速くて均一分散をもたらすものとみる。こ
の粒子表面の皮膜形成が粒子強度を高める働きもしてい
る。The mechanism by which the granulated product of the present invention provides physical properties that are fine-grained, have a high particle strength, and have good dispersibility in water can be estimated as follows. That is, at the same time that the sugar alcohol acts between the aggregated particles of the inorganic antacid during spray-drying granulation and acts to suppress shrinkage, and at the same time, a portion thereof precipitates on the particle surface to form a film, so that the water wetting is improved, As a result, by facilitating the incorporation of water into the disintegrant in the fine-grained particles, it is considered that the dispersibility is high and uniform dispersion is achieved. The formation of a film on the surface of the particles also functions to increase the particle strength.
【0013】本発明の無機制酸剤含有速分散性造粒物の
製造方法及び生成物の理化学的性質を以下の実施例及び
比較例に示す。なお、各々の実施例又は比較例の処方の
成分量は表1に、その理化学的性質は表2に、また水分
散時の口中の官能試験の結果は表3に示した。The following examples and comparative examples show the method for producing the inorganic antacid-containing fast-dispersing granules of the present invention and the physicochemical properties of the products. Table 1 shows the amounts of the components of the formulations of Examples and Comparative Examples, Table 2 shows the physicochemical properties thereof, and Table 3 shows the results of the sensory test in the mouth when dispersed in water.
【0014】[0014]
実施例1 50Lの容器に精製水25kgを入れ、撹拌しながらマ
ンニトール0.50kg、デキストリン0.48kg、
パラオキシ安息香酸メチル0.01kg、アスパルテム
0.01kg、乾燥水酸化アルミニウムゲル4.50k
g及び水酸化マグネシウム4.00kgをそれぞれ順次
加え、ホモジナイザーで均一に分散させる。その後、噴
霧乾燥造粒機(ニロ社製、S−50N/R型)を用い、
ノズル口径1.4mm、入熱温度230〜240℃、排
熱温度130〜140℃で、フィード圧10〜12kg
/cm2で噴霧乾燥し、造粒物9.5kgを得た。得ら
れた造粒物の見掛け密度は0.43であり、安息角は3
2°であった。Example 1 25 kg of purified water was placed in a 50 L container, and while stirring, mannitol 0.50 kg, dextrin 0.48 kg,
Methyl paraoxybenzoate 0.01 kg, aspartame 0.01 kg, dried aluminum hydroxide gel 4.50 k
g and 4.00 kg of magnesium hydroxide are sequentially added, and the mixture is uniformly dispersed with a homogenizer. Then, using a spray-drying granulator (N-50, S-50N / R type)
Nozzle diameter 1.4mm, heat input temperature 230-240 ° C, exhaust heat temperature 130-140 ° C, feed pressure 10-12kg
/ Cm 2 to obtain 9.5 kg of granules. The apparent density of the obtained granules is 0.43 and the angle of repose is 3
2 °.
【0015】実施例2〜5 実施例1の方法に準拠して表1の実施例2〜5の欄に示
す処方により、実施例2〜5の各々の球形造粒物を得
た。その収量は、実施例2(9.2kg)、実施例3
(9.3kg)、実施例4(9.4kg)及び実施例5
(9.4kg)であった。Examples 2 to 5 Spherical granules of Examples 2 to 5 were obtained according to the formulations shown in the columns of Examples 2 to 5 in Table 1 in accordance with the method of Example 1. The yield was as shown in Example 2 (9.2 kg), Example 3
(9.3 kg), Example 4 (9.4 kg) and Example 5
(9.4 kg).
【0016】比較例1及び2 実施例1の方法に準拠して表1の比較例1及び2に示す
処方により、比較例1及び2の球形造粒物を得た。その
収量は、比較例1(9.3kg)及び比較例2(9.4
kg)であった。Comparative Examples 1 and 2 Spherical granules of Comparative Examples 1 and 2 were obtained according to the formulations shown in Comparative Examples 1 and 2 in Table 1 based on the method of Example 1. The yield was as follows: Comparative Example 1 (9.3 kg) and Comparative Example 2 (9.4
kg).
【0017】比較例3及び4 表1の比較例3及び4の欄に示す処方原料を撹拌造粒機
(パウレック製、バーチカル・グラニュレーター、VG
−25)に投入後、ブレード回転数300r.p.
m.、クロススクリュー回転数3000r.p.m.で
5分間混合し、次に水3.70kgを5分間で添加し、
更に5分間撹拌して得られた造粒物を棚式乾燥機で85
℃で7時間乾燥後、不定形造粒物を得た。Comparative Examples 3 and 4 Prescription raw materials shown in the columns of Comparative Examples 3 and 4 in Table 1 were mixed with a stirring granulator (manufactured by Powrex, Vertical Granulator, VG).
-25), the blade rotation speed is 300 r. p.
m. , Cross screw rotation speed 3000r. p. m. And mix for 5 minutes, then add 3.70 kg of water in 5 minutes,
The granulated product obtained by further stirring for 5 minutes is subjected to 85
After drying at 7 ° C. for 7 hours, an amorphous granule was obtained.
【0018】比較例5 比較例3及び4の方法に準拠して、表1の比較例5の欄
に示す処方で70%エタノールを4.00kg用いて撹
拌造粒し、以下、比較例3と4の同様の方法で調製し、
不定形造粒物を得た。Comparative Example 5 In accordance with the method of Comparative Examples 3 and 4, the mixture was stirred and granulated using 4.00 kg of 70% ethanol according to the formulation shown in the column of Comparative Example 5 in Table 1. Prepared in a similar manner as in 4,
An amorphous granulate was obtained.
【0019】上記実施例1〜5及び比較例1〜5の処方
を下記表1にまとめて示す。表中の各成分は重量(k
g)で示されていて、各成分の合計量は実施例1〜5及
び比較例1〜2では10.0kgであり、比較例3〜5
では各々5.0kgである。The formulations of Examples 1 to 5 and Comparative Examples 1 to 5 are shown in Table 1 below. Each component in the table is weight (k
g), the total amount of each component is 10.0 kg in Examples 1 to 5 and Comparative Examples 1 and 2, and Comparative Examples 3 to 5
Each weighs 5.0 kg.
【0020】下記表2は各実施例及び比較例で得られた
生成物の粒子強度試験〔74μmpass(%)〕、崩
壊試験(分)、水分散での粒度分布〔50%平均粒子径
(μm)、最大粒子径(μm)〕及び安息角の測定結果
を示す。Table 2 below shows the particle strength test [74 μpass (%)], the disintegration test (minute), the particle size distribution in water dispersion [50% average particle diameter (μm) of the products obtained in each of Examples and Comparative Examples. ), Maximum particle diameter (μm)] and the angle of repose are shown.
【0021】また、下記表3は、上記各実施例及び比較
例で得られた造粒物の水分散時の口中での官能試験の結
果を示す。表中、の記号は以下の意味を示す(◎は全く
ざらつきがない、○はほとんどざらつきがない、△は少
しざらつきがある、×はざらつきが強い)。Table 3 below shows the results of a sensory test in the mouth when the granules obtained in the above Examples and Comparative Examples were dispersed in water. In the table, the symbols have the following meanings (◎ indicates no roughness, ○ indicates almost no roughness, Δ indicates slight roughness, and × indicates strong roughness).
【0022】[0022]
【表1】 [Table 1]
【0023】[0023]
【表2】 [Table 2]
【0024】[0024]
【表3】 [Table 3]
【0025】試験方法 (1)粒子強度試験 試料10gを秤り、錠剤摩損度試験器(萱垣医理科製4
G−18型)にφ10mm、6R、φ2mmのガラスビ
ーズ10gと共に入れ、10分間回転させた後、74μ
mの篩で試料を篩過し、通過(pass)量を秤量し、
試料10gで除して74μm通過量をパーセンテージで
表す。この数値が高いほど粒子強度が弱く粉化しやす
い。Test Method (1) Particle Strength Test A sample of 10 g was weighed, and a tablet friability tester (4 manufactured by Kayagaki Medical Science Co., Ltd.)
G-18 type) together with 10 g of glass beads of φ10 mm, 6R, φ2 mm, and rotated for 10 minutes.
m, sieve the sample through a sieve, weigh the amount of pass,
Divide by 10 g of sample and show the amount of 74 μm passage as a percentage. The higher the value, the weaker the particle strength and the easier it is to powder.
【0026】(2)崩壊試験 日局崩壊試験装置を用いて以下の方法で崩壊試験を行っ
た。試料をメッシュ150μmの篩でふるい、篩い上の
残留物0.1gをメッシュ150μmの網を取り付けた
補助筒中に入れ、37℃水中で上下運動を行う。試料の
残留物が補助筒内に、認めなくなるまでの時間を測定し
た。崩壊の早いものほど短時間で残留物が消失する。(2) Disintegration Test A disintegration test was conducted by the following method using a disintegration test apparatus of the Japanese Pharmacopoeia. The sample is sieved with a 150 μm mesh sieve, and 0.1 g of the residue on the sieve is placed in an auxiliary cylinder equipped with a 150 μm mesh net, and vertically moved in water at 37 ° C. The time until no residue of the sample was observed in the auxiliary cylinder was measured. The faster the disintegration, the shorter the residue disappears.
【0027】(3)水分散での粒度分布測定試験 レザー回折式粒度分布測定装置(日機装製とマイクロト
ラックMKIISPA型)を使って、水に分散させた試
料の粒度分布を測定した。50%平均粒子径と最大粒子
径を表4と表5に示した。(3) Particle Size Distribution Measurement Test in Water Dispersion The particle size distribution of the sample dispersed in water was measured using a laser diffraction type particle size distribution analyzer (Nikkiso and Microtrac MKIISPA type). Tables 4 and 5 show the 50% average particle size and the maximum particle size.
【0028】(4)安息角の測定 安息角測定装置(パウダーテスタ、ホソカワミクロン
製)を用い、所定量の試料を静かに振とうさせながら、
測定用テーブルに落とし、テーブルの周囲から試料がこ
ぼれはじめたら振とうを停止し、分度器で安息角を測定
する。この安息角が低いほど流動性が良い。(4) Measurement of angle of repose Using a repose angle measuring device (powder tester, manufactured by Hosokawa Micron), while gently shaking a predetermined amount of sample,
Drop the sample on the measuring table. When the sample starts to spill from around the table, stop shaking and measure the angle of repose with a protractor. The lower the angle of repose, the better the fluidity.
【0029】(5)水分散時の口中での官能試験 口中でのざらつきをパネラー5名(男子3名、女子2
名)による官能試験によって評価した。すなわち、水1
0mL中に試料1gを添加し、手で軽く揺すり分散さ
せ、懸濁液剤とし、3分後に口に全量を含みざらつき感
を評価した。(5) Sensory Test in Mouth at the Time of Dispersion in Water 5 panelists (3 boys, 2 girls)
) Was evaluated by a sensory test. That is, water 1
1 g of the sample was added to 0 mL, and the mixture was slightly shaken and dispersed by hand to prepare a suspension. After 3 minutes, the whole mouth was contained and the roughness was evaluated.
【0030】表2の結果からは、実施例1〜5の処方得
られる本発明の造粒物は、粒子強度が硬くて粉化し難
く、且つ水への分散が速い、また分散粒子が微細で原料
粒子に近い状態になり口に含んでもまろやかでざらつき
感がないことが判る。一方、比較例1と比較例5の処方
による造粒物は粒子強度が弱く、水への均一分散もやや
遅く口に含むとざらつき感がある。比較例2、比較例3
及び比較例4の処方による造粒物は粒子強度は硬く粉化
し難いものであるが、水に分散させた場合は崩壊が遅く
凝集物が多く残り、また口に含むとざらつき感が強い。From the results shown in Table 2, it can be seen that the granules of the present invention obtained from the formulations of Examples 1 to 5 have a high particle strength, are hard to be powdered, are rapidly dispersed in water, and have fine dispersed particles. It turns out that it is in a state close to the raw material particles, and even if it is contained in the mouth, it is not round and rough. On the other hand, the granulated products according to the formulations of Comparative Examples 1 and 5 have a low particle strength, and even when dispersed in water a little later, they have a rough feeling. Comparative Example 2, Comparative Example 3
The granulated product according to the formulation of Comparative Example 4 has a high particle strength and is hardly powdered. However, when dispersed in water, it disintegrates slowly and many agglomerates remain.
【0031】[0031]
【発明の効果】本発明により、無機制酸剤、糖アルコー
ル及び崩壊剤を均一に分散させ、噴霧乾燥させることに
より得られる、極めて短時間に水媒質に懸濁分散可能
な、無機制酸剤含有速分散性造粒物及びその製造方法を
提供することができた。本発明の造粒物は、粒子強度が
硬くて粉化し難く保管が容易であり、且つ水への分散が
速く、また分散粒子が微細で原料粒子に近い状態になり
口に含んでもまろやかでざらつき感がなく、用時懸濁内
服制酸剤として最適である。さらにこの造粒物は、携帯
に便利で、服用時、水媒質に極めて迅速に均一に懸濁分
散し、且つ違和感を持たずに服用し得る細粒状無機制酸
剤含有速分散性造粒物であり、消化促進、消化不良、食
欲不振、食べ過ぎ、胃もたれ、胸つかえ、消化不良によ
る胃部・腹部膨満感、胃痛、胃酸過多等の症状の改善に
用いられる用時懸濁内服用制酸剤として極めて有用であ
る。Industrial Applicability According to the present invention, an inorganic antacid which can be suspended and dispersed in an aqueous medium in a very short time, obtained by uniformly dispersing an inorganic antacid, a sugar alcohol and a disintegrant and spray-drying it. It was possible to provide a rapidly dispersible granulated material and a method for producing the same. The granulated product of the present invention has a hard particle strength, is hard to be powdered, is easy to store, is quick to be dispersed in water, and is in a state where the dispersed particles are fine and close to the raw material particles and are round and rough even when included in the mouth. It has no sensation and is most suitable as an antacid in suspension when used. Further, the granulated material is a fast-dispersing granule containing a fine inorganic antacid, which is convenient to carry, can be suspended and dispersed very quickly and uniformly in an aqueous medium when taken, and can be taken without feeling uncomfortable. It is used to improve digestion, indigestion, anorexia, eating too much, leaning the stomach, holding on to the chest, stomach and abdominal distension due to indigestion, stomach pain, and gastric acidity. Very useful as an acid agent.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 高見 潔 富山県中新川郡上市町横法音寺55番地 富 士化学工業株式会社内 (72)発明者 稲垣 満二 富山県中新川郡上市町横法音寺55番地 富 士化学工業株式会社内 (72)発明者 村上 達夫 富山県中新川郡上市町横法音寺55番地 富 士化学工業株式会社内 ──────────────────────────────────────────────────続 き Continuing on the front page (72) Inventor Kiyoshi Takami 55 Kamiichi-cho, Kamiichi-cho, Toyama Prefecture Inside Fuji Chemical Industry Co., Ltd. Address Fuji Chemical Co., Ltd. (72) Inventor Tatsuo Murakami 55 Yokohoonji Temple, Kamiichi-cho, Nakashinagawa-gun, Toyama Prefecture Fuji Chemical Co., Ltd.
Claims (7)
び崩壊剤を均一に分散させ、噴霧乾燥させることにより
得られる無機制酸剤含有速分散性造粒物。1. An inorganic antacid-containing rapidly dispersible granule obtained by uniformly dispersing an inorganic antacid, a sugar alcohol and a disintegrant in an aqueous medium and spray-drying.
水酸化マグネシウム、メタケイ酸アルミン酸マグネシウ
ム、ケイ酸アルミン酸マグネシウム、合成ヒドロタルサ
イト、乾燥水酸化アルミニウムゲル、炭酸マグネシウ
ム、沈降炭酸カルシウムの群から選ばれる1種以上から
なる請求項1記載の無機制酸剤含有速分散性造粒物。2. The inorganic antacid is aluminum hydroxide gel,
The inorganic compound according to claim 1, comprising at least one selected from the group consisting of magnesium hydroxide, magnesium metasilicate aluminate, magnesium aluminate silicate, synthetic hydrotalcite, dried aluminum hydroxide gel, magnesium carbonate, and precipitated calcium carbonate. Acid agent-containing rapidly dispersible granules.
95重量%である請求項1〜2記載の無機制酸剤含有速
分散性造粒物。3. The amount of the antacid is 50 to 50% of the total amount of the granulated product.
The inorganic antacid-containing fast-dispersing granule according to claim 1, which is 95% by weight.
ル、キシリトール、還元麦芽糖水飴、エリスリトールか
らなる群から選ばれる1種以上からなる請求項1〜3記
載の無機制酸剤含有速分散性造粒物。4. The inorganic antacid-containing fast-dispersing granule according to claim 1, wherein the sugar alcohol is at least one selected from the group consisting of sorbitol, mannitol, xylitol, reduced maltose syrup, and erythritol.
トリン、カルメロースカルシウム、部分アルファー化デ
ンプンからなる群から選ばれる1種以上である請求項1
〜4記載の無機制酸剤含有速分散性造粒物。5. The disintegrant is at least one selected from the group consisting of corn starch, dextrin, carmellose calcium, and partially pregelatinized starch.
5. The rapidly dispersible granulated product containing an inorganic antacid according to any one of items 4 to 4.
び崩壊剤を均一に分散させ、噴霧乾燥させることを特徴
とする請求項1〜5記載の無機制酸剤含有速分散性造粒
物の製造方法。6. The inorganic antacid-containing fast-dispersing composition according to claim 1, wherein the inorganic antacid, sugar alcohol and disintegrant are uniformly dispersed in an aqueous medium and spray-dried. A method for producing granules.
性造粒物を有効成分として含有することを特徴とする用
時懸濁内服制酸剤。7. An antacid preparation for oral use in suspension containing the inorganic antacid-containing fast-dispersing granules according to claim 1 as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29450396A JP3961596B2 (en) | 1996-10-15 | 1996-10-15 | Inorganic antacid containing fast dispersible granule, method for producing the same, and suspended internal antacid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29450396A JP3961596B2 (en) | 1996-10-15 | 1996-10-15 | Inorganic antacid containing fast dispersible granule, method for producing the same, and suspended internal antacid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10120554A true JPH10120554A (en) | 1998-05-12 |
| JP3961596B2 JP3961596B2 (en) | 2007-08-22 |
Family
ID=17808625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP29450396A Expired - Lifetime JP3961596B2 (en) | 1996-10-15 | 1996-10-15 | Inorganic antacid containing fast dispersible granule, method for producing the same, and suspended internal antacid |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3961596B2 (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000086537A (en) * | 1998-09-11 | 2000-03-28 | Fuji Chem Ind Co Ltd | Inorganic compound saccharide composition, vehicle, rapidly disintegrating compression molded product, and their production |
| JP2002154940A (en) * | 2000-11-16 | 2002-05-28 | Nonogawa Shoji Kk | Hair decolorant |
| JP2004536855A (en) * | 2001-07-16 | 2004-12-09 | アストラゼネカ・アクチエボラーグ | Pharmaceutical formulations containing proton pump inhibitors and acid neutralizers |
| JP2005538213A (en) * | 2002-09-05 | 2005-12-15 | キンバリー クラーク ワールドワイド インコーポレイテッド | Extrusion cleaning products |
| JPWO2005037254A1 (en) * | 2003-10-15 | 2007-11-22 | 富士化学工業株式会社 | Tablet Quickly Disintegrating in Oral Cavity |
| WO2010098417A1 (en) | 2009-02-25 | 2010-09-02 | 協和化学工業株式会社 | Magnesium oxide fine granules |
| US7838033B2 (en) | 2003-10-15 | 2010-11-23 | Fuji Chemical Industry Co., Ltd. | Composition for rapid disintegrating tablet in oral cavity |
| WO2011019045A1 (en) | 2009-08-11 | 2011-02-17 | 富士化学工業株式会社 | Disintegrating particle composition and orally rapidly disintegrating tablet |
| WO2011019046A1 (en) * | 2009-08-11 | 2011-02-17 | 富士化学工業株式会社 | Disintegrating particle composition and orally rapidly disintegrating tablet |
| JPWO2010092828A1 (en) * | 2009-02-12 | 2012-08-16 | 富士化学工業株式会社 | Disintegrating particle composition and fast disintegrating compression molding using the same |
| US8349361B2 (en) | 2003-10-15 | 2013-01-08 | Fuji Chemical Industry Co., Ltd. | Composition for rapid disintegrating tablet in oral cavity |
| GB2561723A (en) * | 2017-04-18 | 2018-10-24 | Nature Pops Ltd | A composition for oral administration |
| WO2023007766A1 (en) * | 2021-07-30 | 2023-02-02 | セトラスホールディングス株式会社 | Magnesium oxide-containing pharmaceutical composition for treating pediatric chronic functional constipation |
-
1996
- 1996-10-15 JP JP29450396A patent/JP3961596B2/en not_active Expired - Lifetime
Cited By (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000086537A (en) * | 1998-09-11 | 2000-03-28 | Fuji Chem Ind Co Ltd | Inorganic compound saccharide composition, vehicle, rapidly disintegrating compression molded product, and their production |
| JP2002154940A (en) * | 2000-11-16 | 2002-05-28 | Nonogawa Shoji Kk | Hair decolorant |
| JP2004536855A (en) * | 2001-07-16 | 2004-12-09 | アストラゼネカ・アクチエボラーグ | Pharmaceutical formulations containing proton pump inhibitors and acid neutralizers |
| JP2005538213A (en) * | 2002-09-05 | 2005-12-15 | キンバリー クラーク ワールドワイド インコーポレイテッド | Extrusion cleaning products |
| US7838033B2 (en) | 2003-10-15 | 2010-11-23 | Fuji Chemical Industry Co., Ltd. | Composition for rapid disintegrating tablet in oral cavity |
| US8647668B2 (en) | 2003-10-15 | 2014-02-11 | Fuji Chemical Industry Co., Ltd. | Tablet quickly disintegrating in oral cavity |
| JPWO2005037254A1 (en) * | 2003-10-15 | 2007-11-22 | 富士化学工業株式会社 | Tablet Quickly Disintegrating in Oral Cavity |
| JP4726628B2 (en) * | 2003-10-15 | 2011-07-20 | 富士化学工業株式会社 | Orally rapidly disintegrating tablets |
| US8349361B2 (en) | 2003-10-15 | 2013-01-08 | Fuji Chemical Industry Co., Ltd. | Composition for rapid disintegrating tablet in oral cavity |
| JPWO2010092828A1 (en) * | 2009-02-12 | 2012-08-16 | 富士化学工業株式会社 | Disintegrating particle composition and fast disintegrating compression molding using the same |
| WO2010098417A1 (en) | 2009-02-25 | 2010-09-02 | 協和化学工業株式会社 | Magnesium oxide fine granules |
| AU2010218737B2 (en) * | 2009-02-25 | 2014-07-31 | Kyowa Chemical Industry Co., Ltd. | Magnesium oxide granules |
| CN102333535A (en) * | 2009-02-25 | 2012-01-25 | 协和化学工业株式会社 | Magnesium Oxide Microparticles |
| JPWO2010098417A1 (en) * | 2009-02-25 | 2012-09-06 | 協和化学工業株式会社 | Magnesium oxide fine granules |
| WO2011019045A1 (en) | 2009-08-11 | 2011-02-17 | 富士化学工業株式会社 | Disintegrating particle composition and orally rapidly disintegrating tablet |
| WO2011019046A1 (en) * | 2009-08-11 | 2011-02-17 | 富士化学工業株式会社 | Disintegrating particle composition and orally rapidly disintegrating tablet |
| US8900602B2 (en) | 2009-08-11 | 2014-12-02 | Fuji Chemical Industry Co., Ltd. | Disintegrating particle composition and orally rapidly disintegrating tablet |
| JP5674667B2 (en) * | 2009-08-11 | 2015-02-25 | 富士化学工業株式会社 | Disintegrating particle composition and intraoral quick disintegrating tablet |
| JP5674666B2 (en) * | 2009-08-11 | 2015-02-25 | 富士化学工業株式会社 | Disintegrating particle composition and intraoral quick disintegrating tablet |
| US9446055B2 (en) | 2009-08-11 | 2016-09-20 | Fuji Chemical Industry Co., Ltd. | Disintegrating particle composition and orally rapidly disintegrating tablet |
| GB2561723A (en) * | 2017-04-18 | 2018-10-24 | Nature Pops Ltd | A composition for oral administration |
| GB2561723B (en) * | 2017-04-18 | 2022-06-08 | Nature Pops Ltd | A composition for oral administration |
| WO2023007766A1 (en) * | 2021-07-30 | 2023-02-02 | セトラスホールディングス株式会社 | Magnesium oxide-containing pharmaceutical composition for treating pediatric chronic functional constipation |
| JPWO2023007766A1 (en) * | 2021-07-30 | 2023-02-02 | ||
| JP2023020835A (en) * | 2021-07-30 | 2023-02-09 | セトラスホールディングス株式会社 | Magnesium oxide-containing pharmaceutical composition for treating pediatric chronic functional constipation |
| AU2021457908B2 (en) * | 2021-07-30 | 2025-09-04 | Setolas Holdings, Inc. | Magnesium oxide-containing pharmaceutical composition for treating pediatric chronic functional constipation |
| AU2021457908B9 (en) * | 2021-07-30 | 2026-02-05 | Setolas Holdings, Inc. | Magnesium oxide-containing pharmaceutical composition for treating pediatric chronic functional constipation |
| AU2025275199B2 (en) * | 2021-07-30 | 2026-05-14 | Setolas Holdings, Inc. | Magnesium oxide-containing pharmaceutical composition for treating pediatric chronic functional constipation |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3961596B2 (en) | 2007-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4213867B2 (en) | Method for preparing oral calcium composition | |
| JP4748627B2 (en) | Excipient | |
| KR101590115B1 (en) | Pharmaceutical compositions | |
| JP6196676B2 (en) | Rapidly disintegrating solid dosage formulation containing functionalized calcium carbonate and method for producing the same | |
| JPWO1997031639A1 (en) | Tablets containing β-lactam antibiotics and method for producing the same | |
| WO1997031639A1 (en) | TABLETS CONTAINING β-LACTAM ANTIBIOTIC AND PROCESS FOR PRODUCING THE SAME | |
| JPWO2000003735A1 (en) | excipients | |
| WO2010021300A1 (en) | Novel excipient for mannitol tableting | |
| JP3961596B2 (en) | Inorganic antacid containing fast dispersible granule, method for producing the same, and suspended internal antacid | |
| JP3900245B2 (en) | Intraoral rapidly disintegrating tablet and method for producing the same | |
| CN103284968B (en) | Oral cavity disintegration tablet of a kind of aripiprazole composition microcrystalline and preparation method thereof | |
| JPH08502073A (en) | Calcium polycarbophil sprinkle | |
| JP2001322927A (en) | Low substituted hydroxypropylcellulose-containing solid preparation and production method thereof | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| JP5799061B2 (en) | Granular solid formulation containing tosufloxacin and polyvinylpyrrolidone | |
| JP4596586B2 (en) | Trehalose particles | |
| JP7745371B2 (en) | Zonisamide drug substance particles and their uses | |
| EP0599767A1 (en) | Process to prepare water-dispersable tablets containing diclofenac | |
| CN114767652B (en) | Polycarbofil calcium dry suspension and preparation method and application thereof | |
| JP7360460B2 (en) | Orally disintegrating tablet and its manufacturing method | |
| JP5132090B2 (en) | Epinastine hydrochloride dry syrup | |
| AU2019306315B2 (en) | Pharmaceutical composition in the form of a chewable tablet of diosmin or of a flavonoid moiety | |
| CN101237850A (en) | Pharmaceutical composition containing indomethacin and/or acemetacin | |
| HK40128954A (en) | Cool-melting granular composition and preparation method therefor | |
| WO2020032159A1 (en) | Particulate composition and production method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070418 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070517 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130525 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160525 Year of fee payment: 9 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |